Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) in the framework of the Council Decision on new psychoactive substances

Series type: Risk assessments

Summary

This publication presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that ADB-CHMINACA should be subject to control measures across the Member States.

Download as PDF

Table of contents

  • Foreword
  • EMCDDA actions on monitoring and responding to new drugs
  • Europol–EMCDDA Joint Report on ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) — a summary
  • Risk Assessment Report on a new psychoactive substance: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA)
  • Technical report on N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA)
  • Participants of the risk assessment meeting, 7-8 November 2017

Council Implementing Decision on subjecting ADB-CHMINACA to control measures

Keywords: 

NPS

Pages: 
83
Price: 
Free
ISBN: 
978-92-9497-281-1
ISSN: 
1725-4493
Pub. DOI: 
10.2810/473009
Catalog Number: 
TDAK18001ENN
Loading